IL6 and primary cutaneous T-cell non-Hodgkin lymphoma: NGS technology detected mutations that affect the IL6-JAK1-STAT3 pathway in approximately 15–30% of cases, which places JAK/STAT as a candidate target for new personalized treatments in this CTCL subtype.